Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Navneet S MajhailDaniel J Weisdorf

Abstract

The hematopoietic cell transplantation specific comorbidity index (HCT-CI) has been recently proposed to predict the probability of nonrelapse mortality (NRM) and overall survival (OS) in allogeneic HCT recipients while taking into account any pretransplant comorbidity. We tested the validity of the HCT-CI in a cohort of 373 adult HCT recipients (184 matched-related donor and 189 unrelated umbilical cord blood) who received a myeloablative (N = 150) or nonmyeloablative (N = 223) conditioning regimen. HCT-CI scores of 0, 1, 2, and > or =3 were present in 58 (16%), 56 (15%), 64 (17%), and 195 (52%) patients, respectively. Pulmonary conditions were the most common comorbidity. Cumulative incidence of NRM at 2 years was 10%, 20%, 24%, and 28% for HCT-CI scores of 0, 1, 2, and > or =3, respectively (P = .01). The corresponding probability of OS at 2 years was 72%, 67%, 51%, and 48%, respectively (P < .01). On multivariate analyses adjusted for recipient age, disease risk, donor source, and conditioning regimen intensity, the relative risks for NRM for HCT-CI scores of 1, 2, and > or =3 (compared to a score of 0) were 2.0 (95% confidence intervals, 0.8-5.3), 2.6 (1.0-6.7), and 3.2 (1.4-7.4), respectively. The risks for overall mortal...Continue Reading

References

Aug 10, 2006·Current Opinion in Immunology·Navneet S MajhailJohn E Wagner
Aug 29, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohamed L SorrorRainer Storb
Nov 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marco MielcarekRainer Storb

❮ Previous
Next ❯

Citations

Oct 6, 2009·Bone Marrow Transplantation·T E DeForC T Le
Jan 15, 2010·Current Opinion in Hematology·Brian L McClune, Daniel J Weisdorf
Jan 18, 2011·Hematology·Mohamed L Sorror
May 5, 2009·Seminars in Oncology Nursing·Nonniekaye Shelburne, Margaret Bevans
Jul 19, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Aya NakayaShinichiro Okamoto
Sep 14, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Michael J BurkeMichael R Verneris
Feb 11, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Barbara DeschlerJürgen Finke
May 20, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mohamed L SorrorRainer F Storb
Oct 22, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·William A WoodSergio A Giralt
Jan 13, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Erica D WarlickDaniel Weisdorf
Jun 29, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nicole BirningerJohannes Schetelig
Jun 9, 2016·Bone Marrow Transplantation·M Elsawy, M L Sorror
Nov 28, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Meng LvXiao-Jun Huang
Aug 12, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Rashmika PotdarRoni Shouval

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.